Skip Navigation LinksHome > January 2011 - Volume 24 - Issue 1 > A Matched Cohort Study of the Risk of Cancer in Users of Bec...
Advances in Skin & Wound Care:
doi: 10.1097/01.ASW.0000392922.30229.b3
Features: Original Investigations

A Matched Cohort Study of the Risk of Cancer in Users of Becaplermin

Ziyadeh, Najat MPH, MA; Fife, Daniel MD; Walker, Alexander M. MD, DrPH; Wilkinson, Gregg S. PhD, MA; Seeger, John D. PharmD, DrPH

Collapse Box


BACKGROUND: Becaplermin is recombinant human platelet-derived growth factor for topical administration that might plausibly be related to cancer risk. Extended follow-up of patients from clinical trials of becaplermin compared with placebo identified a relative risk of cancer of 2.8 (95% confidence interval [CI], 0.6-12.8). The authors aimed to further investigate any association between becaplermin use and the occurrence of cancer by following a large cohort of patients in a clinical practice setting.

METHODS: In a cohort of insured people, becaplermin initiators were matched to similar people who did not initiate becaplermin and were followed for up to 6 years for cancer incidence (up to 9 years for cancer mortality). Cancer incidence was identified from health insurance claims and validated by review of medical records. Cancer mortality was identified through linkage to the National Death Index.

RESULTS: Among 1622 becaplermin initiators, there were 28 confirmed cancers and 9 cancer deaths, and among the 2809 matched comparators, there were 43 confirmed cancers and 16 cancer deaths. There was no increased risk of cancer with becaplermin (hazard ratio, 1.2; 95% CI, 0.7-1.9). Cancer mortality through 2003 was increased (rate ratio [RR] = 5.2; 95% CI, 1.7-17.6) among subjects with 3 or more dispensings. Additional follow-up through 2006 indicated no elevated cancer mortality risk overall (RR, 1.0; 95% CI, 0.5-2.3) and no statistically significant increase in the subgroup with more than 3 dispensings (RR, 2.4; 95% CI, 0.8-7.4).

CONCLUSIONS: Becaplermin does not appear to increase the risk of cancer or cancer mortality.

© 2011 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.